

CORRECTION

Open Access



Correction to: Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study

Maggie McCue^{1*}, Sara Sarkey¹, Anna Eramo², Clement François² and Sagar V. Parikh³

Correction to: BMC Psychiatry 21, 622 (2021)
<http://orcid.org/10.1186/s12888-021-03608-1>

Following publication of the original article [1], the authors identified errors in the text. Below is a table of corrections which have been implemented in the original article.

Section	Originally published text	Corrected text
Abstract	Treatment response and remission rates were 65 and 40%, respectively.	Treatment response and remission rates were approximately 65 and 40%, respectively.

Results - Baseline characteristics	Overall, study participants were predominantly white (69.2%), female (82.8%), and ≤55 years of age (77.9%). Mean PHQ-9 score was 15.7 (moderately severe depression), and 59.5% of the patients were employed.	Overall, study participants were predominantly white (69.2%), female (82.8%), and ≤55 years of age (77.9%). Mean PHQ-9 score was 15.7 (moderately severe depression), and 58.3% of the patients were employed.
Results - Safety and tolerability	Overall, 117 AEs were reported by 59 patients.	Overall, 117 AEs deemed related to study treatment were reported by 59 patients.
Availability of Data and Materials	The Goal Attainment Scale adapted for depression (Global Attainment Scale – Depression © 2021 Takeda Pharmaceuticals U.S.A., Inc. All rights reserved)	The Goal Attainment Scale adapted for depression (Goal Attainment Scale – Depression © 2021 Takeda Pharmaceuticals U.S.A., Inc. All rights reserved)

The original article [1] has been corrected.

The original article can be found online at <https://doi.org/10.1186/s12888-021-03608-1>.

*Correspondence: Maggie.McCue@takeda.com

¹ Takeda Pharmaceuticals U.S.A., Inc., 95 Hayden Avenue, Lexington, MA 02421, USA

Full list of author information is available at the end of the article

Author details

¹Takeda Pharmaceuticals U.S.A., Inc., 95 Hayden Avenue, Lexington, MA 02421, USA. ²Lundbeck LLC, 6 Parkway North Blvd, Deerfield, IL 60015, USA. ³University of Michigan Health, 1500 E. Medical Center Dr, Ann Arbor, MI 48109, USA.



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Published online: 07 March 2022

Reference

1. McCue M, et al. Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study. *BMC Psychiatry*. 2021;21:622. <https://doi.org/10.1186/s12888-021-03608-1>.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

